0 Where Science Means Business The case of Yissum – The Hebrew University of Jerusalem Renee...
-
Upload
justin-williams -
Category
Documents
-
view
215 -
download
0
Transcript of 0 Where Science Means Business The case of Yissum – The Hebrew University of Jerusalem Renee...
1
Where Science Means Business The case of Yissum – The Hebrew University of JerusalemRenee Ben-Israel, Vice-President – Intellectual Property
WIPO: Information Meeting on Intellectual Property Financing
Geneva – 10 March 2009
Summary
Introduction Patent strategy Patents and Universities Israel’s technology and Innovation Israeli universities Yissum Food for thought
Patents use
Patent strategy may be: Defensive - no intention of developing the invention,
main interest: preventing others from doing so. Dominating - plan to use the technology, the processes
described in their patents and sue infringing parties. Licensing purposes (in/out/cross)-
individuals/institutions that do not intend to manufacture the invention themselves, transfer the rights for development and production to a third party
Other purposes (profit centres, aggregators, “trolls”)
Universities patents strategy?
Not really Depends on the invention!
Platform (enabling) inventions Niche/complementary inventions Use inventions Conceptual inventions
University patents are meant for technology transfer
University patents
University classical mission: Teaching, researching and divulging the knowledge
Universities’ patents: Embryonic – feasibility/market unknown Development requires high risk investment by industry
Intellectual property protection can be used as an incentive to make high risk investment motivating the “first mover” by protecting against
later competitors (strategy!)
Purposes of University Technology Transfer
Participate in innovation process Facilitate the commercialization of research
results for the public good Retain and recruit researchers Create closer ties to industry Generate income for further research and
education Promote economic growth Social responsibility
Purposes of University Technology Transfer
Research => Invention (and IP)=> Development => Innovation
New products and medicines Bring new technology into industry for economic
competitiveness Encourage entrepreneurship for local and national
economic development
(source: Lita Nelsen – MIT)
The Tech Transfer Bargain
University research leads to patent—but technology is unproven and high risk
University is willing to grant exclusive patent license to Company who will commit to the risk of developing the technology
If development succeeds, the patent protects the Company from competitors
University benefits from product being developed and from royalties (shared with inventor)
University also has the opportunity in the license to assure that patents are used “in the public interest”—requiring certain price or geographical concessions for developing countries, if appropriate
(source: Lita Nelsen – MIT)
Patent protection is particularly critical for development of pharmaceuticals
Development of a new therapeutic or vaccine product is a particularly high risk activity Time frames are long Financial investment is very high Clinical trials are very difficult Probability of failure is high
Patent protection of the final product is necessary before companies (or biotech investors) will take the risk and make the investment
(source: Lita Nelsen – MIT)
Pharmaceuticals
Israel: data
Area - Total 120,770 / 22,072 km2 (151st)8,019 / 8,522 sq mi - Water (%)~2%
Population - 2008 estimate 7,282,0002[3] (96th) - 1995 census 5,548,523 - Density324/km2 (34th)839/sq mi
GDP (PPP)2007 estimate - Total$188.936 billion[4] (52nd) -
Per capita$27,146[4] (32nd)GDP (nominal)2007 estimate - Total$164.103
billion[4] - Per capita$23,578[4]
Israel, facts & figures
Technology transfer pioneer Brain power + need =>
use of science to survive,
overcome situations Highest % of R&D allocation from GDP
(4.7% - 2007)
R&D expenditure
1. National Expenditure on Civilian R&D, at 2005 Prices1995-2007
02468
10121416182022242628303234
1995 96 97 98 99 2000 01 02 03 04 2005 *06 *07
N
IS B
illion
*Provisional Data
National expenditure on civilian R&D in 2007 was 4.7% of the GDP. Major increase in R&D companies.
Israel, facts & figures
1901- TEVA’s foundation 1924- The Technion (Polytechnic Institute) 1925- The Hebrew University of Jerusalem Population with high scientific level, strong
inclination to engineering and biological/medical sciences
Research units in hospitals – many experimental units
Access to…
Israel, facts & figures – patentsOECD: Israel has the highest percentage of patents in the region:
Israel is ranked 6 globally for patents per GDP and 8th for patents per capita
Israel: Supporting Infrastructure The Technological Incubators programme, the Tnufa programme, the Noffar fund, the R&D fund. State initiatives matched with private interest meant to foster early stage projects.
Israel: Supporting InfrastructureThe Magnet, the Mini-Magnet, the generic R&D meant to support joint industry & academic institutions cooperations
Israeli Universities
Tech Transfer since 1959 (much before the Bayh-Dole act in the US!)
At all 7 universities & many research institutions, hospitals
Yeda: one of the wealthiest in the world Yissum: 15th in the world
Success stories – a sample
Yeda: Bio-Hep B®, recombinant hepatitis B vaccine Copaxone®, 1st. Innovative drug in Israel, MS
immunomodulator Dunaliella®, β carotene health food form alga NDS Ltd., Encryption Algorithm, TV set-top box smart cards Erbitux ®, Antibody therapy with synergism with
chemotherapy
Technion: Azilect®, Parkinsons Disease
And many others
20
Over 1/3 of all academic scientific research In Israel
43% of Israel’s biotechnology research
>1/3 of PhD students in Israel
4 Campuses
5 Affiliated Hospitals
24,000 Students
1,000 Researchers (Staff Members)
1,600 Post-Graduate Students in Biotechnology
320 Researchers in Applied Sciences
4,420 Research Projects
>100 Research Centres
The Hebrew University of Jerusalem
21
A Nobel Heritage
2002 Nobel Prize in Economics Daniel Kahneman, Princeton
2004 Nobel Prize in Physics David J. Gross, UC Santa Barbara
2004 Nobel Prize in Chemistry Avram Hershko, Technion Aaron Ciechanover, Technion
2005 Nobel Prize in Economics Robert J. Aumann, Hebrew University
2006 Nobel Prize in Chemistry Roger Kornberg, Stanford
22
Top 20 Most Frequently Cited PapersStem Cells 1998-2004
23
http://www.milkeninstitute.org/pdf/m2m2006_uni_bio.pdf
24
Board of Directors Business leaders
Yissum Business-oriented organization
Founded 1964
The Hebrew University Non-profit organization
Where Science Means Business
University Strategy
Created a positive atmosphere at the University
Established good and clear policies as an incentive to researchers
Budget incentives New opportunities Awards/prizes for achievements
26
Yissum’s Mission
To promote the transfer of Hebrew University technology for the benefit of society, while maximizing returns to support research, education and scientific excellence
Yissum = Hebrew for ‘application’
It’s not that simple!
Academic world Business world (Industry, VCs, Start-ups)
(to say nothing about market instabilities…)
Intellectual Property legal world Contracts – legal/commercial world
The rules of the games are different.
Yissum’s strategy
Identifies the right situations - matching needs & opportunities
Identifies the key elements – to move the project forward
Flexibility
Professionalism
With no interference in the academic freedom!
29
Current Snapshot
Over $1 Billion annual sales of Hebrew University- based products
5,500 patents 1,600 inventions 480 licenses 65 spin-offs
Raised over $165 mil in 2007 from leading VCs and private investors
30
A Record of Achievement
2007 revenues $51mil $36 mil royalties and licensing $4.3mil portfolio companies $10mil sponsored research & services
HU research budget $107mil
Ranked in top 15 worldwide (AUTM) Leading US TTO revenues FY2007
MIT $61mil Research budget: $1.2 Billion
Stanford $50mil Research budget: $1 Billion
31
Intellectual Property
2007 Snapshot 121 new inventions 93 new patent applications 64 new patents granted
Intellectual Property at HU Yissum owns all IP
developed at HU Researchers receive
40-60% of revenues
2007 New Inventions
Agriculture11%
Applied Physics2%
Cleantech6%
Computer Science & Engeneering
9%
Life Science and Biotechnology
67%
Materials5%
32
2008 statistics:
Disclosures: 128 New applications filed: 112 PCTs: 44 National Phases: 41/159 (~4 countries) Examination: ~250 Renewals: 500-550 Budget: ~$3M
Patents are an expensive game
0
20
40
60
80
100
120
0 12 20 30 40 50 60 7yrs 12
NP Maintenance
Time
K$
Months
FirstFiling
PCT IPER NPPatentGrant
Prosecution
(Total: 20 years)
34
Global Reach
35
Yissum’s Spin-offs
Rav-Galai
36
Long Shelf Life & CherryTomatoes
The world’s most popularcocktail hybrids for greenhouse production
Prof. Nachum KedarProf. Haim Rabinowich Department of Field Crops,Vegetables and Genetics:Faculty of Agriculture, FoodAnd Environmental Sciences The Hebrew UniversityRehovot Campus 2007 sales $73 million
Success Stories - Tomatoes
37
38
DOXIL®Doxorubicin HCI liposome injection Alza’s Lead Product for Oncology Prof. Yechezkel Barenholz Department of BiochemistryFaculty of Medicine The Hebrew UniversityOf Jerusalem 2007 sales $417 million
Success Stories - Doxil
39
For Treatment of Alzheimer’sDisease and Dementia Prof. MartaWeinstock-Rosin Department of PharmacologyFaculty of Medicine The Hebrew UniversityOf Jerusalem 2007 sales $632 million
Success Stories - Exelon
Food for thought
Will emphasis on tech transfer change nature of research from “discovery” to “applied”?
Will need to collaborate with industry be allowed to inhibit publication and dissemination of results?
Food for thought
Will “privatization” of research results retard the progress of science?
Will the universities remember their public mission—taking care that IP is used primarily for the public good?
Food for thought
Will the decrease in government investments in research create a dependency from commercial sources?
Will this deviate universities from their missions?
It will certainly require a coordinated effort and thought of all involved parts!
Conclusion:
Is it worth the effort?
So far, our experience has been positive!
44
Thank you for your attention!